STOCK TITAN

Armistice (GCTK) reports 9.99% stake — 101,075 shares disclosed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Glucotrack, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 101,075 common shares, representing 9.99% of the class as of 12/31/2025.

The filing states the shares are held with shared voting and dispositive power of 101,075. The Master Fund, a Cayman Islands client of Armistice Capital, has the right to receive dividends or sale proceeds for these securities. Signatures date the filing 02/17/2026.

Positive

  • None.

Negative

  • None.

Insights

Armistice reports a near-10% position with shared control over 101,075 shares.

Armistice Capital, LLC and Steven Boyd disclose beneficial ownership of 101,075 shares or 9.99% of Glucotrack common stock as of 12/31/2025. The position is reported with shared voting and dispositive power rather than sole control.

The filing notes the Master Fund (Cayman) as having rights to dividends or sale proceeds. Subsequent filings may clarify whether the stake is passive or part of an active strategy; timing of any holder action is not provided in the excerpt.

Schedule 13G used for beneficial ownership disclosure under passive/qualified investor rules.

The joint filing names Armistice Capital, LLC and Steven Boyd as Reporting Persons and includes a joint filing statement. The reported 9.99% ownership sits below common 10% thresholds that often trigger different reporting classifications.

The excerpt explicitly attributes dividend/proceeds rights to the Master Fund, a client of Armistice, and is signed 02/17/2026. Further amendments could follow if holdings change or control attributes shift.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

Glucotrack

NASDAQ:GCTK

GCTK Rankings

GCTK Latest News

GCTK Latest SEC Filings

GCTK Stock Data

1.67M
821.39k
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
RUTHERFORD